PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Jul 29

PMID 32718075

Citations 12

Authors

John A Katzenellenbogen

Affiliations

Soon will be listed here.

Abstract

Many breast and prostate cancers are driven by the action of steroid hormones on their cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit hormone production or block the action of these receptors provide clinical benefit to many but not all of these cancer patients. Because it is difficult to predict which individuals will be helped by endocrine therapies and which will not, positron emission tomography (PET) imaging of estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer, and androgen receptor (AR) in prostate cancer can provide useful, often functional, information on the likelihood of endocrine therapy response in individual patients. This review covers our development of three PET imaging agents, 16α-[F]fluoroestradiol (FES) for ER, 21-[F]fluoro-furanyl-nor-progesterone (FFNP) for PgR, and 16β-[F]fluoro-5α-dihydrotestosterone (FDHT) for AR, and the evolution of their clinical use. For these agents, the pathway from concept through development tracks with an emerging understanding of critical performance criteria that is needed for successful PET imaging of these low-abundance receptor targets. Progress in the ongoing evaluation of what they can add to the clinical management of breast and prostate cancers reflects our increased understanding of these diseases and of optimal strategies for predicting the success of clinical endocrine therapies.

Citing Articles

5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

West-Szymanski D, Zhang Z, Cui X, Kowitwanich K, Gao L, Deng Z JCO Precis Oncol. 2024; 8():e2400277.

PMID: 39393034 PMC: 11729496. DOI: 10.1200/PO.24.00277.

Characterization of an Estrogen Receptor α-Selective F-Estradiol PET Tracer.

Sluka P, Ackermann U, Rigopoulos A, Wardan H, Pezaro C, Burvenich I World J Nucl Med. 2024; 23(3):153-160.

PMID: 39170834 PMC: 11335392. DOI: 10.1055/s-0044-1786518.

Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.

Raina K, Forbes C, Stronk R, Rappi Jr J, Eastman K, Zaware N Cell Chem Biol. 2024; 31(8):1490-1502.e42.

PMID: 39116881 PMC: 11371387. DOI: 10.1016/j.chembiol.2024.07.005.

Molecular Imaging of Steroid Receptors in Breast Cancer.

Keigley Q, Fowler A, OBrien S, Dehdashti F Cancer J. 2024; 30(3):142-152.

PMID: 38753748 PMC: 11101139. DOI: 10.1097/PPO.0000000000000715.

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.

Yoon S, Bazan J Curr Oncol Rep. 2024; 26(6):647-664.

PMID: 38652425 PMC: 11168988. DOI: 10.1007/s11912-024-01529-2.

References

Wagner H . SNM highlights as history: 1983. J Nucl Med. 2003; 44(7):33N-37N. View

Shi J, Afari G, Bhattacharyya S . Rapid synthesis of [18F]fluoroestradiol: remarkable advantage of microwaving over conventional heating. J Labelled Comp Radiopharm. 2014; 57(14):730-6. PMC: 4275410. DOI: 10.1002/jlcr.3248. View

Pomper M, Pinney K, Carlson K, van Brocklin H, Mathias C, Welch M . Target tissue uptake selectivity of three fluorine-substituted progestins: potential imaging agents for receptor-positive breast tumors. Int J Rad Appl Instrum B. 1990; 17(3):309-19. DOI: 10.1016/0883-2897(90)90058-9. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Chan S, Fowler A, Allen J, Zhou D, Dence C, Sharp T . Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy. Clin Cancer Res. 2014; 21(5):1063-70. PMC: 4348221. DOI: 10.1158/1078-0432.CCR-14-1715. View

Katzenellenbogen J, Hsiung H, Carlson K, McGuire W, KRAAY R, Katzenellenbogen B . Iodohexestrols. II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo. Biochemistry. 1975; 14(8):1742-50. DOI: 10.1021/bi00679a029. View

Kumar M, Salem K, Tevaarwerk A, Strigel R, Fowler A . Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer. J Nucl Med. 2019; 61(2):172-176. PMC: 8801958. DOI: 10.2967/jnumed.119.228858. View

Ali H, Rousseau A, van Lier J . Synthesis of (17 alpha,20E/Z)iodovinyl testosterone and 19-nortestosterone derivatives as potential radioligands for androgen and progesterone receptors. J Steroid Biochem Mol Biol. 1994; 49(1):15-29. DOI: 10.1016/0960-0760(94)90296-8. View

Rijks L, van den Bos J, van Doremalen P, Boer G, De Bruin K, Janssen A . New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterization. Nucl Med Biol. 1998; 25(8):791-8. DOI: 10.1016/s0969-8051(98)00042-0. View

10.

. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999; 97(2):161-3. DOI: 10.1016/s0092-8674(00)80726-6. View

11.

Allott L, Miranda C, Hayes A, Raynaud F, Cawthorne C, Smith G . Synthesis of a benzoxazinthione derivative of tanaproget and pharmacological evaluation for PET imaging of PR expression. EJNMMI Radiopharm Chem. 2019; 4(1):1. PMC: 6328429. DOI: 10.1186/s41181-018-0054-z. View

12.

Dehdashti F, Mortimer J, Siegel B, Griffeth L, Bonasera T, Fusselman M . Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995; 36(10):1766-74. View

13.

Hoyte R, Rosner W, JOHNSON I, Zielinski J, Hochberg R . Synthesis and evaluation of potential radioligands for the progesterone receptor. J Med Chem. 1985; 28(11):1695-9. DOI: 10.1021/jm00149a027. View

14.

Salman M, Chamness G . A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone. J Med Chem. 1991; 34(3):1019-24. DOI: 10.1021/jm00107a021. View

15.

Landvatter S, Katzenellenbogen J . Nonsteroidal estrogens: synthesis and estrogen receptor binding affinity of derivatives of (3R*,4S*)-3,4-bis(4-hydroxyphenyl)hexane (hexestrol) and (2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentane (norhexestrol) functionalized on the side chain. J Med Chem. 1982; 25(11):1300-7. DOI: 10.1021/jm00353a006. View

16.

Ghanadian R, Waters S, Chisholm G . Investigations into the use of 77Br labelled 5alpha-dihydrotestosterone for scanning the prostate. Eur J Nucl Med. 1977; 2(3):155-7. DOI: 10.1007/BF00257273. View

17.

Katzenellenbogen J, Mathias C, VanBrocklin H, Brodack J, Welch M . Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding.... Nucl Med Biol. 1993; 20(6):735-45. DOI: 10.1016/0969-8051(93)90160-v. View

18.

Rathkopf D, Morris M, Fox J, Danila D, Slovin S, Hager J . Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013; 31(28):3525-30. PMC: 3782148. DOI: 10.1200/JCO.2013.50.1684. View

19.

Katzenellenbogen J, Hsiung H . Iodohexestrols. I. Synthesis and photoreactivity of iodinated hexestrol derivatives. Biochemistry. 1975; 14(8):1736-41. DOI: 10.1021/bi00679a028. View

20.

Grill H, Heubner A, Pollow K, Manz B, SCHULZE P, Hofmeister H . (Z)-17 beta-hydroxy-17 alpha-(2-[125I]iodovinyl)-4-estren-3-one: a new specific gamma-emitting ligand for determination of progesterone receptor. J Clin Chem Clin Biochem. 1987; 25(2):107-12. View